Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma
暂无分享,去创建一个
A. Gasbarrini | F. Giuliante | G. Torzilli | G. Rapaccini | R. Sacco | C. Campani | A. Mega | F. Foschi | G. Raimondo | F. Trevisani | E. Biasini | C. Celsa | F. Morisco | G. Grazi | A. Ruzzenente | E. Jovine | G. Baiocchi | A. Ferrero | M. Maestri | S. Famularo | G. Griseri | R. D. Valle | D. Bernasconi | M. Crespi | M. Donadon | R. Memeo | G. S. Baroni | M. Chiarelli | S. Ferri | L. Aldrighetti | F. Cipriani | Filippo Pellizzaro | F. Romano | A. Antonucci
[1] K. Hasegawa,et al. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors , 2022, Journal of hepato-biliary-pancreatic sciences.
[2] A. Gasbarrini,et al. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison. , 2022, Annals of surgery.
[3] V. Cristini,et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.
[4] J. Bruix,et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.
[5] Shelly C. Lu,et al. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis , 2021, Liver Cancer.
[6] Jonathan M. Hernandez,et al. Patient Comorbidities Drive High Mortality Rates Associated with Major Liver Resections Irrespective of Hospital Volume , 2020, The American surgeon.
[7] F. Giuliante,et al. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience , 2020, Updates in Surgery.
[8] Alessandro Vitale,et al. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy , 2020, Hepatology.
[9] F. Piscaglia,et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. , 2019, Journal of hepatology.
[10] R. Figlin,et al. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. , 2019, The oncologist.
[11] L. Gianotti,et al. The impact of age and ageing on hepatocarcinoma surgery: Short‐ and long‐term outcomes in a multicentre propensity‐matched cohort , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[12] A. Gasbarrini,et al. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice , 2018, Hepatology.
[13] H. Tilg,et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma , 2017, Gut.
[14] P. Malfertheiner,et al. Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study , 2017, Clinical Cancer Research.
[15] J. Marrero,et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.
[16] M. Kudo,et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. , 2016, Journal of hepatology.
[17] C. Newgard,et al. Missing Data: How to Best Account for What Is Not Known. , 2015, JAMA.
[18] C. Sakakura,et al. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. , 2015, World journal of gastroenterology.
[19] M. Makuuchi,et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. , 2014, Journal of hepatology.
[20] P. Austin,et al. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study , 2014, Statistical methods in medical research.
[21] M. Kudo,et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis , 2013, International journal of clinical practice.
[22] P. Austin. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.
[23] M. Choti,et al. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group , 2013, Annals of surgery.
[24] M. Colombo,et al. Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy , 2011, Hepatology.
[25] W. Lau,et al. Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus , 2010, Annals of Surgical Oncology.
[26] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[27] G. Torzilli,et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. , 2008, Archives of surgery.
[28] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[29] M. Makuuchi,et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.
[30] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[31] M. Makuuchi,et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. , 1999, Archives of surgery.
[32] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[33] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[34] F. Tambo. The Clavien-Dindo Classification of Surgical Complications , 2012 .
[35] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[36] M. Makuuchi,et al. The Brisbane 2000 terminology of liver anatomy and resections. , 2000 .
[37] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.